{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-39UQ2G8T/473b31c6-1c45-482a-b4e1-2459bd30e662/PDF","dcterms:extent":"247 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-39UQ2G8T/13c84984-416b-42f8-95b8-7b26f0e6d460/TEXT","dcterms:extent":"40 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-39UQ2G8T","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2023","dc:creator":["Ban, Helena","Belak Magdalenić, Urška","Korošec, Sara"],"dc:contributor":"Korošec, Sara","dc:format":[{"@xml:lang":"sl","#text":"številka:11/12"},{"@xml:lang":"sl","#text":"letnik:92"},{"@xml:lang":"sl","#text":"str. 496-503"}],"dc:identifier":["DOI:10.6016/ZdravVestn.3420","ISSN:1318-0347","COBISSID:179358467","URN:URN:NBN:SI:doc-39UQ2G8T"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"endometriosis"},{"@xml:lang":"sl","#text":"endometrioza"},{"@xml:lang":"sl","#text":"estrogen"},{"@xml:lang":"sl","#text":"maligna transformacija"},{"@xml:lang":"en","#text":"malignant transfomation"},{"@xml:lang":"sl","#text":"menopavza"},{"@xml:lang":"sl","#text":"menopavzno hormonsko zdravljenje"},{"@xml:lang":"en","#text":"meopause"},{"@xml:lang":"en","#text":"oestrogen"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Obravnava endometrioze v pomenopavznem obdobju| Endometriosis management after menopause|"},"dc:description":[{"@xml:lang":"sl","#text":"Endometriosis is a disease that can affect 2-5% of all postmenopausal women. It is a disease in which the glands and stro-ma of the uterus are located outside the maternity area. To date, little is known in the literature about endometriosis in menopausal women. Diagnostic concerns currently relate mainly to concerns about possible malignancy. Reports in the literature describe the recurrence of endometriosis in the postmenopausal period as well as the occurrence of endome-triosis de novo. The treatment of choice for symptomatic endometriosis in menopause is the surgical removal of all visible endometriotic tissue, as the risk of recurrence and conversion to malignancy is relatively high. Postmenopausal hormone therapy (MHT) is often used to relieve postmenopausal symptoms and prevent bone loss. There are studies showing that MHZ can reactivate endometriotic foci and even promote malignant transformation of foci in women with a history of endometriosis. Considering the risks of MHZ in patients, which are not fully known, special caution should be exercised with this therapy"},{"@xml:lang":"sl","#text":"Endometrioza je bolezen, ki lahko prizadene 2–5 % vseh žensk v pomenopavznem obdobju. Gre za bolezen, pri kateri se endometrijske žleze in stroma nahajajo zunaj maternice. O pomenopavzni endometriozi je zaenkrat v literaturi še malo znanih podatkov. V sklopu diagnosticiranja je v tem obdobju v ospredju predvsem skrb, da gre morda za maligno bolezen. Poročila v literaturi opisujejo ponovitev endometrioze v pomenopavznem obdobju kot tudi nastanek endometrioze »de novo«. Zdravljenje izbire simptomatske endometrioze v pomenopavzi je kirurško z odstranitvijo vsega vidnega endome-triotičnega tkiva zaradi višjega tveganja za ponovitev bolezni in preobrat v maligno bolezen. Hormonsko zdravljenje po menopavzi (MHZ) se pogosto uporablja za lajšanje simptomov in preprečevanje izgube kostne mase. Obstajajo raziskave, ki dokazujejo, da MHZ lahko ponovno aktivira endometriotična žarišča in celo spodbuja maligno preoblikovanje žarišč pri ženskah z anamnezo endometrioze. Glede na ne povsem razjasnjena tveganja MHZ pri tovrstnih bolnicah se svetuje dodatna previdnost"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-39UQ2G8T","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-39UQ2G8T"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-39UQ2G8T/473b31c6-1c45-482a-b4e1-2459bd30e662/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-39UQ2G8T/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-39UQ2G8T"}}}}